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ABSTRACT
Necrotic enteritis toxin B (NetB) is a pore-forming toxin produced by Clostridium perfringens and
has been shown to play a key role in avian necrotic enteritis, a disease causing signiﬁcant costs
to the poultry production industry worldwide. The aim of this work was to determine whether
immunization with a non-toxic variant of NetB (NetB W262A) and the C-terminal fragment of
C. perfringens alpha-toxin (CPA247–370) would provide protection against experimental
necrotic enteritis. Immunized birds with either antigen or a combination of antigens
developed serum antibody levels against NetB and CPA. When CPA247–370 and NetB W262A
were used in combination as immunogens, an increased protection was observed after oral
challenge by individual dosing, but not after in-feed-challenge.
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Introduction
Necrotic enteritis (NE) is a severe gastro-intestinal dis-
ease causing signiﬁcant costs to the poultry industry
worldwide (Parish, 1961; Keyburn et al., 2008; Cooper
& Songer, 2009). Disease can occur either as an acute
clinical or as a mild subclinical form. Acute NE typi-
cally leads to high mortality rates during the last
weeks of the broiler rearing period. Disease can arise
without any previous signs and cause mortality in a
couple of hours (Helmboldt & Bryant, 1971; Wijewanta
& Senevirtna, 1971). However, most of the NE cases are
associated with relatively mild clinical signs (Kaldhus-
dal & Hofshagen, 1992; Brennan et al., 2001a, 2001b).
This subclinical form of NE is chronic and induces
intestinal damage. Diseased birds show reduced per-
formance parameters such as less feed intake,
decreased digestion and absorption of feedstuffs and
consequently reduced weight gain over time (Elwinger
et al., 1992; Kaldhusdal et al., 2001). The mild subclini-
cal form is believed to be the most prevalent form of
NE and mostly responsible for the associated economic
losses as it may go undetected and remain untreated
(Dahiya et al., 2006).
Clostridium perfringens, a commensal of the intestinal
microbiota, has been shown to be the causative agent of
NE. A number of predisposing factors have been ident-
iﬁed which inﬂuence the gut environment of the host
organism and favour the growth of NE-inducing
C. perfringens strains. The nature of the feedstuff is the
key predisposing factor for NE. Poorly digestible diets,
such as non-starch polysaccharides and protein-rich
feed, lead to ideal growth conditions for C. perfringens
in the gut (Branton et al., 1987; Riddell and Kong,
1992; Palliyeguru et al., 2010). Sudden diet changes,
high-density bird housing conditions or extreme
environmental temperatures are other important factors
that predispose to NE (McDevitt et al., 2006; Burkholder
et al., 2008).Mucosal damage of the gut, caused byorgan-
isms such as Eimeria species, has often been reported
before or during outbreaks of NE in the ﬁeld (Helmboldt
& Bryant, 1971; Broussard et al., 1986; Williams, 2005).
Co-infection of C. perfringens with Eimeria species has
been shown to synergistically induce NE (Alsheikhly &
Alsaieg, 1980; Williams et al., 2003; Gholamiandehkordi
et al., 2007; Park et al., 2008). The molecular makeup of
C. perfringens strains present in the gut is another essen-
tial factor (Shojadoost et al., 2012).Most ofC. perfringens
isolates from cases of NE possess the netB gene (Chal-
mers et al., 2008; Cooper & Songer, 2009; Martin &
Smyth, 2009), encoding the necrotic enteritis toxin B
(NetB), a member of the Staphylococcus aureus α-hemo-
lysin-like β-pore-forming toxin family (Keyburn et al.,
2008; Savva et al., 2013). This toxin has a proven role
in NE development (Keyburn et al., 2008).
Vaccine trials against NE initially focused on the use
of C. perfringens alpha-toxin (CPA) as an antigen.
Immunization studies with CPA have been shown to
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partially protect chickens from developing NE
(Kulkarni et al., 2007; Cooper et al., 2009; Kulkarni
et al., 2010). It has been shown that birds with high
CPA titres showed lower mortality rates during the
production period than those with low titres (Heier
et al., 2001). Immunization with either C. perfringens
crude toxoids or culture supernatants can also provide
signiﬁcant protection against experimental NE (Lanck-
riet et al., 2010; Saleh et al., 2011). In addition, a num-
ber of immunogenic proteins from C. perfringens have
been evaluated as sub-unit vaccines providing partial
protection against experimental NE. Although a variety
of antigens have been tested as vaccine candidates
against NE so far, complete protection against disease
has not been reported yet. In a previous study, we
showed that a non-toxic variant of NetB (NetB
W262A) was able to induce partial protection against
experimental NE in poultry (Fernandes da Costa
et al., 2013). In this study we investigated whether a
combination of NetB W262A and a fragment of the
C-terminal domain of CPA (CPA247–370) (Williamson
& Titball, 1993) could provide improved protection
against disease as compared to vaccination with the
individual antigens. Protection was evaluated
using an in-feed and oral administration infection
model.
Materials and methods
Expression and puriﬁcation of NetB W262A and
CPA247–370
Expression and puriﬁcation of NetB W262A or
CPA247–370 was carried out as described previously
(Titball et al., 1993; Williamson and Titball, 1993;
Fernandes da Costa et al., 2013; Savva et al., 2013). In
short, recombinant Escherichia coli expressing the
toxin variants were grown in terriﬁc broth sup-
plemented with ampicillin (100 μg/ml) at 37°C and sha-
ken at 300 rpm. For NetB W262A expression, cultures
were induced at an optical density (OD595nm) of 0.5
for 6 h by adding arabinose at a ﬁnal concentration of
0.02% (w/v). Expression of CPA247–370 was induced at
an OD595nm of 0.5 for 6 h by the addition of IPTG (1
mM ﬁnal concentration). In both cases, bacterial cells
were harvested by centrifugation, lysed enzymatically
using BugBuster (Invitrogen, Paisley, UK) and NetB or
CPA247–370 were puriﬁed with Ni-NTA or GST
GraviTrap chromatography columns (GE Healthcare
Life Sciences, Little Chalfont, UK), respectively, accord-
ing to the manufacturer’s instructions. Buffer was
exchanged by size-exclusion chromatography using
PD-10 desalting columns (GE Healthcare) equilibrated
with Tris-buffered saline (TBS; 20 mM Tris pH 7.5,
150 mM NaCl) and protein concentrations were
measured with a UV–VIS spectrophotometer (Thermo
Scientiﬁc, Cramlington, UK).
Birds and housing conditions
Ross 308 broiler chickens were obtained as one-day-old
chickens (Vervaeke-Belavi Hatchery, Tielt, Belgium)
and the parent ﬂock had not been vaccinated with
the commercial Netvax™ or any other C. perfringens
vaccine. All birds were housed in the same room.
The birds were reared in pens at a density of 26–30
birds per 1.5 m2 on wood shavings. All pens were sep-
arated by solid walls to prevent contact between birds
from different treatment groups. Before the trials,
housing rooms were decontaminated with Metatectyl
HQ (Clim’oMedic®, Metatecta, Belgium) and a com-
mercial anticoccidial disinfectant (OOCIDE, DuPont
Animal Health Solutions, Wilmington, DE, USA).
The chickens received ad libitum drinking water and
feed. Bird experiments were carried out according to
the recommendations and following approval of the
Ethical Committee of the Faculty of Veterinary Medi-
cine, Ghent University, Belgium.
Strains and culture conditions
C. perfringens strain 56 was grown during 18 h at 37°C
in Brain Heart Infusion broth (Oxoid, Basingstoke,
UK) with 0.375% glucose in an anaerobic (84% N2,
8% CO2 and 8% H2) cabinet (Ruskinn Technology,
Bridgend, UK) and used as such.
Vaccine preparation and delivery
On days 3, 9 and 15, chickens were immunized with 30
μg of NetB W262A, CPA247–370 or a combination of
both. In each case, Quil-A (50 μg; Brenntag Biosector,
Frederikssund, Denmark) was used as an adjuvant.
The mixture was diluted in PBS to a total volume of
200 µl, mixed by vortexing and ﬁlter-sterilised (0.2
µm pore size). Birds were vaccinated subcutaneously
in the neck with a 200 µl dose. Controls consisted of
an untreated group and a group receiving only the
Quil-A adjuvant.
In vivo NE model
For each trial, ﬁve groups of 26–30 (indicated in
Table 1) one-day-old Ross 308 broiler chickens were
fed a wheat/rye-based (43%/7.5%) diet, with soybean
meal as protein source. The feed composition was as
described elsewhere (Gholamiandehkordi et al.,
2007). Brieﬂy, the diet contained high levels of (bird)
proteins and non-starch polysaccharides which predis-
pose to the development of NE. Nobilis Gumboro D 78
vaccine (Schering-Plough Animal Health, Brussels,
Belgium) was given in the drinking water on day 16.
From day 17 onwards, soy bean meal was replaced by
ﬁshmeal (30%) as a protein source.
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Trial 1 was carried out to compare the efﬁcacy of
vaccination of individual antigens with a combination
of antigens using an infection model causing mild dis-
ease. The NEmodel of the ﬁrst trial was based on a sub-
clinical in vivo model described previously (Mot et al.,
2012). The birds were challenged orally, using a plastic
tube inserted in the crop, on days 17, 18, 19 and 20 with
a single dose of approximately 4 × 108 colony-forming
units of C. perfringens strain 56. On day 18, all birds
were orally inoculated with a 10-fold dose of Para-
cox-5 (Schering-Plough Animal Health). On days 21,
22 and 23, one-third of the birds in each group were
euthanized and necropsied.
Trial 2 was carried out to clarify whether vacci-
nation yielded the same protection when a more severe
challenge model was used. In the second trial an in-
feed-challenge was performed based on the model by
Keyburn et al. (2006). High level protein feed (30%
ﬁshmeal) and Brain Heart Infusion broth culture
were manually mixed in a ratio of 3:4 (v/w). The mix-
ture was then placed into feed trays. Birds were fed the
culture/feed mixture twice a day, on days 19, 20, 21 and
22. The feed trays were cleaned and the remaining feed
discarded prior to each subsequent feeding. On day 20,
all birds were orally inoculated with a 10× dose of Para-
cox-5 (Schering-Plough Animal Health). The birds
were euthanized and necropsied on day 23.
Measurement of antibodies to NetB and CPA
using ELISA
Antibody responses to NetB W262A and CPA247–370
immunization were determined using an enzyme-
linked immunosorbent assay (ELISA). Serum from 10
chickens was collected individually in all groups, on
day 16 (ﬁrst trial) or day 17 (second trial), and pooled.
For NetB, ELISA was performed as described pre-
viously (Fernandes da Costa et al., 2013). First, 96-
well microtitre plates (Nunc-Immuno Plates,
MaxiSorp, Thermo Scientiﬁc, Cramlington, UK) were
coated with 0.5 µg/well of recombinant wild-type
NetB with N-terminal His tag and incubated overnight
at 4°C. Plates were then washed three times with TBS-T
(TBS, Tween 0.5% v/v) and blocked with TBS-3%
skimmed milk for 1 h at 37°C. Following incubation,
plates were rinsed three times with TBS-T and incu-
bated with 100 µl/well of pooled sera (1:20) in TBS-
1% skimmed milk for 1 h at 37°C. Wells were then
rinsed three times with TBS-T and incubated with a
horseradish peroxidase (horseradish peroxidase)-con-
jugated goat anti-chicken IgY (H + L) secondary anti-
body (Abcam, Cambridge, UK) at a dilution of
1:10,000 in TBS-1% skimmed milk. For detection,
100 μl of tetramethylbenzidine substrate solution was
added to each well and plates were incubated for 30
min at room temperature. The reaction was stopped
by the addition of 100 μl of 3 M H2SO4 and absorbance
was measured at 450 nm using a Model 680 Microplate
Reader (Bio-Rad Laboratories Ltd., Hemel Hempstead,
UK). For CPA detection, the Bio-X CPA ELISA kit
(Bio-X Diagnostics, Jemelle, Belgium) was used accord-
ing to the manufacturer’s instructions. In brief, pooled
sera samples (1:2) were added to a recombinant CPA
sensitized 96-well microtitre plate and incubated for
2 h at 37°C. Wells were then rinsed three times with
washing buffer, HRP-conjugated anti-CPA antibodies
added and plates incubated for 30 min at 37°C. Anti-
body detection was performed using tetramethylbenzi-
dine as described above. Each ELISA was performed in
triplicate.
Assessment of protection
NE severity was assessed by scoring lesions within the
small intestine of each bird (duodenum to ileum) as
described by Keyburn et al. (2006) as follows: 0 = no
gross lesions; 1 = congested intestinal mucosa; 2 =
focal necrosis or ulceration (1–5 foci); 3 = focal necrosis
Table 1. Description of experimental groups used in this study.
Trial Group
Birds/
group Vaccine
Vaccination
dose
Vaccination
day(s)
Serum
collecting
day Challenge
Number of birds
with lesions/
total number
Percentage of birds
with necrotic
enteritis (%)
1 1 27 – – – 16 Orally on days 17, 18,
19 and 20
10/27 37
2 28 Quil A + PBS – 3, 9, 15 16 9/28 32
3 28 NetB W262A 30µg 3, 9, 15 16 5/28 18
4 26 CPA247–370 30µg 3, 9, 15 16 3/26 12
A
5 28 NetB
W262A +
CPA (247–
370)
30µg + 30µg 3, 9, 15 16 0/28 0B
2 1 26 – – – 17 Culture/feed mixture
(3:4) twice a day on
days 19, 20, 21, 22
11/26 42
2 27 Quil A + PBS – 3, 9, 15 17 14/27 52
3 29 NetB W262A 30µg 3, 9, 15 17 8/29 28
4 30 CPA247–370 30µg 3, 9, 15 17 6/30 20
B
5 30 NetB
W262A +
CPA247–370
30µg + 30µg 3, 9, 15 17 9/30 30
Values with uppercase(A) superscripts differ signiﬁcantly (P < 0.01 for trial 1); values with uppercase (B) superscripts differ signiﬁcantly (P < 0.05 for trial 2).
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or ulceration (6–15 foci); 4 = focal necrosis or ulcera-
tion (≥ 16 foci); 5 = patches of necrosis 2–3 cm long;
6 = diffuse necrosis typical of ﬁeld cases. Birds showing
lesion scores of two or higher were classiﬁed as NE
positive.
Statistical analyses
To compare the mean values of antibody levels for the
enzyme linked immunoassay, 1-way analysis of var-
iance analysis was carried out followed by Dunnett’s
multiple comparisons test using GraphPad Prism
5.01 software (GraphPad Software, La Jolla, CA,
USA). For the in vivo NE model, differences between
groups in the occurrence of NE-positive birds were
evaluated by binary logistic regression analysis with
the SPSS Statistics software 22.0 (SPSS Inc., Chicago,
IL, USA). In both analyses, a P value of less than 0.05
was considered as signiﬁcant.
Results
Immune response to NetB W262A and
CPA247–370
An ELISA was used to measure serum antibody
responses to NetB or CPA in the immunized birds.
Blood samples were taken on day 16 or 17, one day
before the ﬁrst C. perfringens challenge. In the ﬁrst
trial chickens immunized with NetB W262A, CPA247–
370 or a combination of both increased antibody
responses to the immunizing antigen relative to the
Quil-A immunized control group (Figure 1(a)). In par-
ticular, a statistically signiﬁcant increase (P < 0.001) was
detected for NetB antibody levels in the NetB W262A
immunized group and when a combination of NetB
W262A and CPA247–370 was used. The second trial con-
ﬁrmed these results (Figure 1(b)). A signiﬁcant increase
(P < 0.05) was detected for NetB antibody levels in the
NetB W262A immunized group and when the combi-
nation NetBW262A and CPA247–370 was used. A signiﬁ-
cant increase was detected for CPA antibody levels in
the CPA247–370 immunized group (P < 0.001) and
when the combination NetB W262A and CPA247–370
was used (P < 0.05).
Protection against experimental NE after
immunization with genetic toxoids
Trial 1
The chickens were challenged orally once a day at days
17, 18, 19 and 20. Immunization with NetB W262A,
CPA247–370 or a combination of both reduced lesion
scores and the occurrence of NE-positive birds relative
to the control groups. While mean lesion scores were
0.74 and 0.75 in the control groups of untreated chick-
ens and those dosed with adjuvant only, respectively,
birds immunized with either NetB W262A or
CPA247–370 showed reduced mean lesion scores to
0.39 and 0.23, respectively (Figure 2(a)). No lesions
were observed after immunization with a combination
of NetB W262A and CPA247–370. In the untreated
chickens or chickens dosed with adjuvant only, 37%
and 32% were NE-positive, respectively, whereas only
18% of the birds immunized with NetB W262A and
12% of the birds immunized with CPA247–370 were
NE-positive (Figure 2(b)). Birds immunized with a
combination of NetB W262A and CPA247–370 showed
no signs of NE.
Trial 2
Chickens were challenged in-feed at days 19, 20, 21 and
22. Again, immunization with NetB W262A, CPA247–
370 or a combination of both reduced lesion scores and
the occurrence of NE-positive birds relative to the control
groups. Mean lesion scores were 1.23 and 1.70 in the con-
trol groups of untreated chickens and those dosed with
adjuvant only, respectively. Chickens immunized with
NetB W262A showed a mean lesion score of 0.79. The
group immunized with CPA247–370 showed a mean lesion
score of 0.56. After immunization with the combination
of NetB W262A and CPA247–370 a mean lesion score of
0.93 was observed (Figure 3(a)). In the untreated chickens
or chickens dosed with adjuvant only, 42% and 52% were
NE-positive, respectively, whereas only 27% of the birds
immunized with NetB W262A and 20% of the birds
immunized with CPA247–370 were NE-positive (Figure 3
(b)). In the group immunized with the combination of
NetB W262A and CPA247–370 30% of the chickens were
NE-positive.
Discussion
In recent years, a number of studies have been carried
out on the development of a potential vaccine against
NE. Signiﬁcant protection has been shown by immu-
nization with crude or inactivated C. perfringens super-
natant (Lanckriet et al., 2010). However, the antigens
responsible for the induction of protective immunity
have not been identiﬁed. A range of recombinant
proteins from C. perfringens has been evaluated as vac-
cines, including glyceraldehyde-3-phosphate dehydro-
genase, pyruvate-ferredoxin oxidoreductase, fructose
1,6-biphosphate-aldolase and a hypothetical protein
(Kulkarni et al., 2007). Immunization with any of
these proteins provided partial protection against
experimental NE. Oral immunization with an attenu-
ated Salmonella enterica serovar Typhimurium vaccine
vector expressing fructose 1,6-biphosphate-aldolase,
the carboxy-terminal domain of CPA or a hypothetical
protein induced protective responses against NE in
chickens (Kulkarni et al., 2008; Zekarias et al., 2008).
Partial protection against NE has also been reported
after immunization with C. perfringens large cytotoxin
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TpeL, endo- β-N-acetylglucosaminidase or phospho-
glyceromutase (Jiang et al., 2009). A more recent
study in which CPA, NetB, pyruvate-ferredoxin oxido-
reductase and elongation factor-Tu were compared as
protective antigens concluded that NetB and pyru-
vate-ferredoxin oxidoreductase given with ISA71 adju-
vant provided the best protective immunity (Jang et al.,
2012). In an attempt to improve the level of protection
afforded by these vaccine antigens, some of these have
been expressed in attenuated mutants of S. enterica
(Zekarias et al., 2008; Kulkarni et al., 2008, 2010).
Whilst these recombinant Salmonella are well suited
for oral delivery, these vaccines also failed to confer
complete protection against disease.
In a previous study, we have shown that immuniz-
ation of poultry with a formaldehyde NetB toxoid or
NetB W262A resulted in the induction of antibody
responses against NetB and provided partial protection
against experimental NE (Fernandes da Costa et al.,
2013). The current study was conducted to test if a
Figure 1. Antibody responses to NetB and CPA using ELISA. Chickens were immunized with NetB W262A, CPA247–370 or a combi-
nation of both, on days 3, 9 and 15. Sera were taken on day 16 prior to C. perfringens challenge. Each bar represents mean ± SEM.
Asterisks indicate a statistically signiﬁcant difference relative to the Quil-A immunized control (*P < 0.05, **P < 0.01 and ***P <
0.001). (a) First trial and (b) second trial.
Figure 2. Data from the in vivo NE model of the ﬁrst trial. Chickens were challenged orally once a day at days 17, 18, 19 and 20. (a)
Lesion scores of individual chickens. According to severity, lesions in the small intestine were scored from 0 (no gross lesions) to 6
(diffuse necrosis). Individual chickens are marked as (+). n = number of birds. (b) NE-positive chickens. Birds with lesion scores of 2
or higher were classiﬁed as NE-positive. Black bars represent SEM. Groups not sharing the indicated letters are signiﬁcantly different
(P < 0.01).
AVIAN PATHOLOGY 385
combination of NetB W262A with CPA247–370, which
individually have been shown to provide partial protec-
tion against disease, provided enhanced protection
relative to single protein immunization. Immunization
led in both trials to increased antibody responses to
NetB and CPA and to protection against experimental
NE. However, the enhanced protection by immuniz-
ation with a combination of NetB W262A and
CPA247–370 depended on the severity of challenge in
the in vivo trials. In the ﬁrst trial, in which an oral
challenge was performed resulting in mild subclinical
disease, the protection in the group vaccinated with
the combination of NetB W262A and CPA247–370
was complete. In the second trial, in which a more
severe in-feed model was used, the protection was
partial.
The importance of the challenge method used in an
in vivo NE-model was already mentioned by Shoja-
doost et al. (2012). The severity of the disease, and
also the protection against the disease, depends
strongly on the challenge method used.
Our data show that vaccination with the combi-
nation of both antigens enhances the protection against
a mild challenge but is not sufﬁcient enough against a
severe challenge. Also, the vaccination scheme used
would not be practical in the ﬁeld since the vaccine
was administered parenterally three times. An alterna-
tive route may lie in breeder hen vaccination, but the
antibody decline in the progeny may decrease efﬁcacy
(Keyburn et al., 2013). Expression of NetB W262A
and CPA247–370 in a bacterial vector could allow this
vaccine to be given by an oral route, such as in drinking
water or feed. Suitable vectors would include attenu-
ated mutants of bacteria, such as attenuated strains of
S. enterica. Alternatively, it may be possible to express
NetB W262A and CPA247–370 in a bacterium that is
normally a member of the poultry gut microbiota,
such as Bacillus species. The use of a live bacterial vec-
tor for expressing antigens, however, would mean the
vaccines would be classiﬁed as genetically modiﬁed
organisms. In contrast to other vaccines they require
special attention concerning their impact on the
environment. The regulatory restrictions of genetically
modiﬁed organisms products are signiﬁcantly larger in
many countries than those for the release of conven-
tional live vaccines (Frey, 2007).
In conclusion, the present study shows the potential
of CPA247–370 and NetB W262A to be used as a combi-
nation vaccine to provide protection against mild NE.
Further studies are required to determine a suitable
delivery route for practical immunization in the poul-
try industry, and to enhance protection.
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